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Summary 
BACKGROUND 
Equine type 1 polysaccharide storage myopathy (PSSM1) is associated with a missense mutation 
(R309H) in the glycogen synthase (GYS1) gene, enhanced glycogen synthase (GS) activity and 
excessive glycogen and amylopectate inclusions in muscle.  
 
METHODS 
Equine muscle biochemical and recombinant enzyme kinetic assays in vitro and homology 
modelling in silico, were used to investigate the hypothesis that higher GS activity in affected 
horse muscle is caused by higher GS expression, dysregulation, or constitutive activation via a 
conformational change. 
 
RESULTS 
PSSM1-affected horse muscle had significantly higher glycogen content than control horse 
muscle despite no difference in GS expression. GS activity was significantly higher in muscle from 
homozygous mutants than from heterozygote and control horses, in the absence and presence 
of the allosteric regulator, glucose 6 phosphate (G6P). Muscle from homozygous mutant horses 
also had significantly increased GS phosphorylation at sites 2+2a and significantly higher 
AMPKα1 (an upstream kinase) expression than controls, likely reflecting a physiological attempt 
to reduce GS enzyme activity. Recombinant mutant GS was highly active with a considerably 
lower Km for UDP-glucose, in the presence and absence of G6P, when compared to wild type 
GS, and despite its phosphorylation. 
 
CONCLUSIONS 
Elevated activity of the mutant enzyme is associated with ineffective regulation via 
phosphorylation rendering it constitutively active. Modelling suggested that the mutation disrupts 
a salt bridge that normally stabilises the basal state, shifting the equilibrium to the enzyme’s active 
state. 
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GENERAL SIGNIFICANCE 
This study explains the gain of function pathogenesis in this highly prevalent polyglucosan 
myopathy. 
 
Key words: PSSM1, polyglucosan, glycogen synthase, glycogen, muscle, glycogen storage 
disease 
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Introduction 
The ability to store glucose as the branched-chain polymer glycogen is shared by organisms as 
evolutionarily diverse as bacteria and mammals: it enables organisms to deal with temporary 
starvation by maintaining energy provision through glycogen catabolism, and, in times of plenty, 
to store this energy macromolecule substrate in a form that has minimal effect on cellular osmotic 
pressure [1]. In mammals, glycogen is normally stored in muscle and other tissues following the 
action of 2 key enzymes: glycogen synthase (GS) and glycogen branching enzyme (GBE). GS 
catalyses the polymerisation of glucose from a UDP-glucose (UDPG) substrate via α1-4 
glycosidic bonds and GBE is responsible for generating α1-6 bonds, every 4-10 residues [2]. 
There are 2 GS isoforms: one, encoded by the GYS1 gene and predominantly expressed in 
muscle but also in other tissues and the other encoded by the GYS2 gene and expressed only in 
liver. Both GS isoforms are regulated by protein kinase-catalysed phosphorylation and allosteric 
modulation by glucose-6-phosphate (G6P) [3].  
 
There are more than 14 glycogen storage diseases in humans and animals [4-7], several of which 
are characterised by excessive muscle glycogen or polyglucosan and caused by enzymatic 
defects in glycogenesis or glycogenolysis. In 2008, a missense, autosomal dominant mutation 
(R309H) in GYS1 was identified in Quarter Horses with polysaccharide storage myopathy 
(PSSM1) [8], a disease characterised by intermittent exertional rhabdomyolysis episodes and 
excessive muscle glycogen and amylopectate accumulation [9, 10] but with an absence of cardiac 
signs [11]. The R309H mutation is associated with increased GS activity in muscle from affected 
horses [8]. The identical mutation has now been reported in many horse breeds worldwide [12-
15] suggesting dissemination from a single founder and in certain breeds, positive selection [16] 
perhaps due to the increased muscle glycogen storage in affected animals [8]. Since the ratio of 
GS: GBE activity is important in the formation of glycogen with a normal structure [17], filamentous 
alpha crystalline polysaccharide that forms in PSSM1-affected muscle likely develops because of 
an increased GS: GBE activity ratio [18] as seen in transgenic mice with constitutively active 
muscle GS [19]. The mechanism by which the equine R309H mutation results in increased GS 
activity is unknown; potential mechanisms include elevated GS expression, reduced degradation 
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or dysregulation of enzyme activity. However, since the R309H mutation occurs in a highly 
conserved region of all GS enzymes and a mutation of an adjacent amino acid in yeast GS 
(equivalent to amino acid G310 in mammalian GS) also results in increased enzyme activity [20], 
it is possible that mutations in this region cause constitutive enzyme activation. 
 
Covalent regulation of GS is dependent on 9 separate phosphorylation sites that are modified by 
various upstream kinases; of these, phosphorylation at sites 2 (serine residue S7), 2a (S10), 3a 
(S641) and 3b (S645) decrease the enzyme activity more than the remaining 5 sites [21-23]. 
Furthermore, phosphorylation of certain sites enables sequential phosphorylation of others so 
that they can be functionally grouped for investigative purposes [24]. Two of the key upstream 
kinases responsible for marked inhibition of GS are glycogen synthase kinase 3β (GSK3β) (which 
phosphorylates sites 3a, 3b, 3c, and 3d) and AMP-activated protein kinase (AMPK), which 
phosphorylates GS at site 2. Other kinases, namely Casein Kinase 2 and Protein kinase A, are 
associated with phosphorylation at sites 1a, 1b and 5 which have little effect on GS activity [24]. 
The phosphorylation of GS has a significant effect on G6P affinity; indeed, regulation by G6P is 
associated with a feed-forward mechanism that causes further enzyme activation by 
dephosphorylation [25]. Although the R309H residue is distant in the primary sequence from any 
of the known phosphorylation sites, the mutation could result in an inappropriate response to 
phosphorylation as is seen in a yeast GS variant [20].  
 
Although the crystal structure has not been published for any mammalian GS, the structures for 
a bacterial GT5 synthase (Agrobacterium tumefaciens) [2] and, more recently, for a yeast 
synthase (Saccharomyces cerevisiae; Gsy2p) [26] and a Caenorhabditis elegans synthase [27] 
have been solved. Yeast GS is a homo-tetrameric protein in both its basal and active states and 
eukaryotic GT3 synthases likely have a similar tetrameric arrangement due to their high sequence 
identity [26]. Since the amino acid sequence surrounding the PSSM1 R309H GYS1 mutation is 
highly conserved amongst species [8] it is possible that this site might have an important (but as 
yet unknown) functional role [2, 28]. It is not however thought to be involved in substrate binding 
[2, 29] or catalytic activity [2, 20, 30]. 
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The binding of the G6P ligand to GS is complex [26]. The structural basis for G6P allosteric 
activation has been revealed from analysis of high-resolution crystal structures of the homologous 
synthase enzyme, Gsy2p from Saccharomyces cerevisiae: GS has a binding pocket for the 
phosphate side chain of G6P that comprises 5 amino acid residues that are conserved across the 
GT3 family glycosyltransferases [26]. G6P binding results in a major conformational change 
involving translation and rotation toward the tetramer interface of the enzyme to generate the 
active form [26]. Co-crystallisation of Gsy2p with maltodextrin polymers (used as analogues to 
detect glycogen binding sites) shows that there are at least 4 maltodextrin sites for this substrate 
in the enzyme’s active form [31]. Only binding sites 1 and 2 are exposed in the basal form of GS 
[31]: these sites might be important for enabling the enzyme to remain bound to glycogen even 
when GS activity is reduced by phosphorylation [32]. 
 
Improved understanding of the mechanism by which the R309H mutation in equine GYS1 leads 
to the mutant enzyme’s increased activity might help further elucidate the functional significance 
of an incompletely characterised domain of this fundamentally important mammalian enzyme. 
Furthermore, it could prompt investigation of specific treatments for this common equine 
myopathy or for other related glycogenoses in humans [33]. In this work, we investigate the 
enzyme’s regulation in silico via computational modelling and through biochemical analysis in 
vitro of whole muscle extracts and via recombinant expressed enzyme kinetics. We hypothesised 
that higher GS activity in affected horse muscles is caused by (1) higher GS expression; (2) 
altered GS regulation by allosteric effectors or by covalent phosphorylation; or (3) constitutive 
activation via a conformational structural change. 
 
Materials and Methods 
Muscle sample collection: 
Muscle samples were collected by open biopsy under local anaesthesia from the 
semimembranosus muscle of 12 homozygous normal (RR), 13 heterozygote (HR) and 4 
homozygous mutant (HH) Belgian and Percheron draught horses according to ethical approval 
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from the Institutional Animal Care and Use Committee (University of Auburn). All horses were 
maintained at the university research facility and were managed at pasture and fed identically. 
Horses were selected on the basis of age- and sex-matching of individuals of differing genotype, 
following genotyping of the entire herd of horses using an established restriction fragment 
polymorphism assay [8]. Samples were snap-frozen in liquid nitrogen, shipped on dry ice and 
stored at -80oC until use. 
 
Glycogen content measurement: 
Total glycogen was measured in 50 mg wet weight muscle biopsy samples using a colorimetric 
assay [34] (RR=7, RH=8, HH=4). 
 
GS activity: 
GS activity was measured using radiolabelled UDP-glucose [35] in the presence of low (0.02 mM), 
medium (0.17 mM) and high (8 mM) G6P concentrations. Calculation of the fractional velocity of 
the enzyme, %FV (100 × [activity (0.17 mM G6P)/activity (8 mM G6P)]) enables investigation of 
the regulation of GS by G6P. Calculation of G6P-independent activity, % I-form (100 × [activity 
(0.02 mM G6P)/activity (8 mM G6P)]) enables investigation of GS regulation by phosphorylation 
[35-37]. 
 
Briefly, 20 μg of homogenised muscle (RR n=12, RH n=13, HH n=4) was placed into wells of a 
96 well plate (Nunc) in duplicate and 40 μl of each of 3 different glucose concentration (final 
glucose concentrations: 0.02 mM, 0.17 mM or 8 mM) reagents were added. Samples were 
incubated with the glucose reagent (containing differing G6P concentrations, 25 mM Tris-HCl, 5 
mM ethylene-diamine-tetra-acetic acid (EDTA), 10 mg/ml glycogen, 50 mM NaF, 2.5 mM 
unlabelled UDPG and 50 μl/ml UDPG (14C)) for 25 minutes at 37oC and then 50 μl of the mixture 
was added to wells of Unifilter 96 well plates (Whatman) containing 200 μl 66% ice-cold ethanol 
in ddH20 water. The plates were then incubated at -20oC for 2h and subsequently washed in ice-
cold 66% ethanol 5 times. Plates were then dried for 15 minutes at 37oC and 75 μl of Microscint 
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40 scintillation fluid (Perkin Elmer) was added to each well before counting using a top-count NXT 
scintillation counter (Perkin Elmer).  
 
Muscle homogenisation:  
For measurement of total GS expression, skeletal muscle homogenates were prepared from 50 
mg of snap frozen biopsy tissue dissected free of any visible fat or connective tissue and crushed 
using a pestle and mortar cooled using dry-ice. The powder was then dissolved in 1 ml of protein 
extraction buffer containing phosphatase inhibitors, heated at 100oC for 5 minutes and 
subsequently centrifuged (16000g for 5 minutes at 4oC). The supernatant was removed and its 
protein concentration measured using the Pierce BCA protein assay.  
 
A modified extraction was performed on skeletal muscle homogenates for measurement of 
phosphorylated isoforms of GS and upstream kinases. 40 mg of frozen muscle was cut into small 
pieces and submerged in 600 μl of protein extraction buffer, before homogenising using a Qiagen 
TissueLyser (2 x 30 seconds at 30000 Hz). The samples were then rotated end over end for 1 h 
at 4oC and protein concentration was then determined as above.  
 
Total glycogen synthase expression:  
Whole muscle protein homogenates were separated using 8% acrylamide gels and transferred 
onto nitrocellulose membranes (Amersham). Total GS expression was measured using a rabbit 
monoclonal antibody to the C-terminus of human GS (Clone EP817Y; Epitomics; 1: 10000) and 
membranes were co-blotted with a mouse monoclonal antibody to human desmin (Clone D33, 
Dako; 1: 50000). Secondary antibodies were HRP-conjugated goat antibodies (either anti-rabbit 
or anti-mouse; BioRad; 1:5000). All antibodies were incubated for 1 hour at room temperature. 
Chemiluminescence was measured with the ECL-prime kit (Amersham) and Amersham Hyperfilm 
ECL (GE Healthcare). Assay linearity was confirmed with pilot experiments via loading of 
increasing amounts of protein per lane (results not shown). Films were digitised using a Stylus 
Photo RX640 printer and scanner (Epson, Hemel Hempstead, UK) alongside a 21-step 
transmission step wedge (Stouffer Graphic Arts, Mishawaka, USA).  The mean grey intensity 
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values from equal rectangular areas of each region of the step wedge were quantified in ImageJ 
(NIH, Bethesda, USA). Total GS expression was calculated as a ratio to desmin expression to 
control for loading. 
 
Phosphorylated GS isoform expression:  
Muscle protein samples were separated using 8% self cast acrylamide gels and then transferred 
using a semi-dry technique (Amersham TE77) onto a PVDF membrane (Millipore).  Sheep 
polyclonal primary antibodies were those used previously against phosphorylation epitopes of 
sites 1b (2μg/ml), 2+2a (4μg/ml) and 3a+3b (1μg/ml) of GS [35, 38]. Appropriate HRP-conjugated 
secondary antibodies were used (Dako; 1:5000). All antibodies were incubated for 1 hour at room 
temperature. Chemiluminesence was measured using Luminata Forte HRP chemiluminescent 
subrstrate (Millipore). After quantification using ImageLab software (Biorad), membranes were 
stripped of antibodies and then re-incubated with a total GS antibody as previously described. 
Results are presented as a ratio of the phosphorylated enzyme to total GS expression.  
 
GLUT4, GSK3 and AMPK phosphorylation and expression: 
Using the same technique as for phosphorylated isoforms of GS, total GLUT4 (Pierce; 1:1000), 
total GSK3β ; 1:500), phosphorylated GSK3β (Cell Signalling; 
1:1000) and AMPK (α1; 1:5000, α2; 1:15000 and β1; 1:1000, as described by Woods et al. [39], 
β2:1:3000, as described by Durante et al. [40] and pAMPK Thr172; 1:1000 from Cell Signalling) 
protein expression levels were measured in whole muscle homogenates. Antibodies directed 
against the AMPK γ1 and γ3 subunits did not detect the equine protein. All primary antibodies 
were diluted in 2% skimmed milk and incubated overnight at 4oC and all secondary antibodies 
were incubated for 45 minutes at room temperature. Appropriate HRP-conjugated secondary 
antibodies were used (Jackson IR; 0.16μg/ml for pGSK3β. Dako; 1:5000 for all others). GLUT4 
and total GSK3β expression were quantified in muscle protein samples using α-actin (Sigma; 
1:8000) as a loading control. Phosphorylated GSK3β was expressed as a ratio to total GSK3β 
expression. AMPK expression was calculated and normalised according to a standard curve 
derived from protein homogenates of known quantities as is custom for this assay [41]. 
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Chemiluminesence was measured using Luminata Forte HRP chemiluminescent substrate 
(Millipore) and quantified using ImageLab software (BioRad). 
 
GS baculovirus cloning and expression 
Full-length amplicons of R309 wild-type and H309 mutant GYS1 cDNAs, obtained from 
homozygous wild-type and homozygous mutant muscle RNA respectively, were cloned into the 
PH promoter of the pFastBac dual vector (Invitrogen) between the BamH1 and Xba1 cloning sites.  
Subsequently, a full-length amplicon of equine glycogenin (GYG1) cDNA was subcloned into the 
p10 promoter of both the wild-type R309 GS*pFastBac and the H309 mutant Gs*pFastbacs 
between the Nhe1 and Xho1 cloning sites, allowing co-expression of active equine GS with equine 
glycogenin in Spodoptera frugiperda Sf9 insect cells. Each of the cloned insert sequences in each 
vector was verified with Sanger sequencing.  Western blot of harvested insect cells from each of 
3 different clones of mutant and wild type vectors was then used to confirm the expression of wild-
type GS and R309H GS together with glycogenin. Large culture volumes of these cells (1 litre) 
were grown and cell pellets harvested by Kinnakeet Biotechnology, USA.  
Purification of recombinant horse glycogen synthase 
The insect cell pellets were resuspended and lysed in 50 ml of extraction buffer containing 50 mM 
Tris-HCl, pH 7.8, 300 mM NaCl, 0.1% Triton X-100, 2 mM EDTA, 1 mM benzamidine, 0.5 mM 
phenylmethanesulfonyl fluoride (PMSF), 10 mM β-mercaptoethanol (BME).  The crude cell 
extracts were centrifuged at 35,000 rpm in a Beckman Ti-45 rotor for 30 minutes at 4˚C and the 
supernatants were collected. Ethanol (kept at -80˚C prior to use) was slowly added to the clarified 
cell lysates, under constant stirring, to a final concentration of 30%. This process was done in an 
ice/salt broth so that the temperature stayed between -1 and -5˚ C, ensuring complete 
precipitation of the endogenous insect cell glycogen (no additional glycogen was added). The 
suspensions were then centrifuged at 9000g for 60 min at -3˚C. The supernatant was discarded 
and the glycogen pellets were resuspended in 100 ml of loading buffer containing 50 mM Tris-
HCl, 300 mM NaCl, 1 mM benzamidine, 0.5 mM PMSF and 2 mM BME. The resuspended pellets 
were then loaded onto a Concanavalin-A (Sigma) column. After washing the column with 20 
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column volumes of loading buffer, the protein was gradient eluted with glucose (0-400 mM). The 
fractions that had GS activity (in the presence of 10 mM G6P) were pooled and then dialysed 
extensively against a buffer containing 50 mM Tris-HCl, 300 mM NaCl and 2 mM BME to remove 
the free glucose. The protein was then concentrated and mixed with glycerol to a final 
concentration of 35% and stored at -20˚ C for long term usage [42].  
 
Specific activity and activity ratio measurement 
GS activity was measured in the recombinant enzymes by the method of Thomas et al. which 
quantifies the amount of 14C-glucose transferred from 14C-labelled UDP-glucose to glycogen over 
a period of 15 min at 30˚C [43]. Standard reaction conditions used 4.44mM UDP-glucose and 
6.67 mg/ml of glycogen. Prior to use, rabbit liver glycogen type-III was deionised by passing it 
through TMD-8 hydrogen and hydroxide form-mixed bed exchanger resins. Activity was 
measured both in the presence or absence of 10 mM G6P and before and after treatment with 
50μg/ml recombinant protein phosphatase 1 (PP1) (gamma) (gift of Dr. Anna DePaoli-Roach, 
Indiana University), the latter in comparison with similarly treated recombinant WT and mutant 
(S7A) human GS (description of S7A mutant given in supplementary methods). In order to 
dephosphorylate phosphorylated serine, threonine and tyrosine residues, 50 µg of different GS  
samples were incubated with 50 µg of PP1 gamma catalytic subunit 1, at 30˚C for 30 minutes. 
The reaction mix also contained 0.2mM MnCl2 which is essential for protein phosphatase 1 
activity. After 30 minutes, GS reaction mix was added (containing 4.44mM UDP-glucose, 6.67 
mg/ml of glycogen, C14 UDP-glucose, 1mM 1,4-dithiothreitol (DTT) and 1mM EDTA (final 
concentrations)). The EDTA present in the GS reaction mix will terminate the phosphatase 
reaction. The activity ratio is the ratio of the activity in the absence of G6P to the activity in the 
presence of 10 mM or 7.2mM G6P (muscle or insect extracts respectively). Protein concentration 
was measured by Bradford’s method, using bovine serum albumin as a standard. 
Enzyme kinetics for UDP-Glucose and Glucose-6-Phosphate 
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For the UDP-glucose titrations, 7 different concentrations of UDPG (0.1 mM to 15 mM for the wild 
type (WT) enzyme and 0.05 mM to 6 mM for the mutant R309H enzyme) were used, keeping the 
glycogen concentration constant at 6.67 mg/ml either in the presence or absence of 10 mM G6P.  
Eight different concentrations of G6P (0.1mM to 20mM for the WT enzyme and 0.05mM to 10mM 
for the mutant R309H enzyme) were used for the G6P titrations under standard reaction 
conditions. 
Kinetic data analysis 
The enzyme kinetic data were analyzed using SigmaPlot (v12.3). The activation curves for G6P 
were fitted to the 4 parameter logistic curve and the S0.5 values were obtained from these fits. The 
substrate saturation curves were fitted to the standard Michaelis-Menten equation v= 
Vmax*[S]/(Km+[S]), where v is the reaction rate, [S] is the substrate concentration, Vmax is the 
maximum rate achieved by the system and Km is the substrate concentration at half maximum 
velocity. The Vmax and Km values were obtained from these fits and the results represent the mean 
of 3 separate experiments. 
Insect protein site 3a phosphorylation 
100ng samples of different GS proteins (as used for kinetic studies) were separated by 10% SDS-
PAGE and transferred onto a 0.45-µm nitrocellulose membrane (Bio-Rad) at 30 V, overnight.  
After transfer, the membranes were blocked in 5% nonfat milk powder in 1X Tris-buffered saline 
(TBS) containing 0.1% Tween 20.  The membrane was then incubated overnight at 4˚ C with 
phospho 3a (Ser641) specific rabbit GS primary antibody obtained from Cell Signaling (3891). 
The membranes were then washed and subsequently incubated with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling, 7074) for 5 h at room temperature. Detection 
was performed by enhanced chemiluminescence using Pierce ECL western blot substrate 
purchased from Thermo Scientific. After detection, the membranes were treated with stripping 
buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate, 0.7% β-mercaptoethanol 
to remove the phospho 3a primary and secondary antibodies. After stripping, the same 
membranes were incubated overnight at 4˚ C with rabbit GS specific primary antibodies (Cell 
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Signaling, 3886). The membranes were then washed, treated with secondary antibodies and 
developed as described above. In all cases, prior to use, the primary and secondary antibodies 
were diluted 1:2000 and 1:4000, respectively. Densitometric analysis of the immunoblots was 
performed using Quantity One software package.  
 
Homology modelling 
X-ray crystal structures of S. cerevisiae Gsy2p in the basal state (PDB code 3NAZ; 3 Å resolution) 
and G6P bound state (PDB code 3NB0; 2.41 Å resolution) provided the templates for homology 
modelling of equine GS. The full-length sequence of equine GS was retrieved from Genbank 
(accession ACB14276) and sequence aligned with S. cerevisiae Gsy2p using Clustal Omega [44]. 
MODELLER software [45] was used to generate 50 models of both the basal and bound 
tetrameric forms of equine GS. In both cases the internal scoring function of MODELLER was 
used to select 10 models that were visually inspected and submitted to the VADAR webserver 
[46] for assessment of stereochemical soundness in order to select a single best model. The 
R309H mutation was introduced into both models using SwissPDBViewer [47]. Model figures 
were generated using PyMOL (DeLano Scientific, San Carlos, CA, U.S.A.). 
 
Statistical analysis: 
Data calculations and statistical analysis were performed using GraphPad Prism (Version 6.0). 
Due to the small sample size for the homozygous mutant group, non-parametric statistics were 
performed and statistical significance was assessed via a Kruskal-Wallis test and Dunn’s post-
hoc multiple comparison test. Results were considered statistically significant when P<0.05.  
Pearson’s correlation was used to examine association between continuous variables.   
 
 
Results 
Breed and signalment data 
There were no significant differences in age, sex or breed of the 3 genotyped groups used for this 
study (Table S1).   
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Muscle glycogen content, GS activity and total GS expression.  
Heterozygote (RH) and homozygote (HH) mutant horses had significantly higher glycogen 
content in skeletal muscle than control (RR) horses (Figure 1A), despite there being no difference 
in total muscle GS expression between each of the genotyped groups (p=0.98) (Figure 1B). The 
higher glycogen content of mutant horse muscle was accompanied by higher GS activity in 
muscle samples from homozygotes (HH) compared to samples from heterozygotes and between 
homozygotes (HH) and WT controls (RR) in the presence (Figure 1C, %FV, p=0.03) and the 
absence of G6P (Figure 1D, %I-form, p=0.04) but there was no difference in maximal GS enzyme 
activity between genotypes (p=0.20, data not shown).  
 
Figure 1: A) Glycogen content of wet weight muscle samples from WT (RR)(n=7), PSSM1-
heterozygotes (RH)(n=8) and PSSM1-homozygotes (HH)(n=4) horses (median +/- min/max 
values, box represents interquartile range; RR vs. RH p=0.005, RR vs. HH p= 0.041, *p<0.05).  
B) Total glycogen synthase expression in muscle homogenates from each of the genotypes 
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was not significantly different (p=0.98). Glycogen synthase activity shown as C) fractional 
velocity (FV) and D) l-form activity. There was an increase in %FV between PSSM1-
homozygotes (HH) and WT controls (RR) (p=0.03) and an increase in %I-form activity between 
heterozygotes (RH) and PSSM1-homozygotes (HH) samples (p=0.04) (median +/- min/max 
values, box represents interquartile range, RR (n= 12), RH (n=13), HH (n=4) *p<0.05).  
 
Phosphorylation of GS 
PSSM1-homozygote muscle samples had greater phosphorylation at site 2+2a than WT samples 
(Figure 2B; p=0.009). There were no detectable differences in levels of GS phosphorylation at 
the other target sites (1b and 3a+3b) between the genotypes (Figure 2A and 2C). 
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Figure 2: Western blot analysis of GS phosphorylation in skeletal muscle homogenates. 
There were no significant differences between the genotypes for phosphorylation of A) p1b 
isoform (p=0.48) and C) p3a+3b isoform (p=0.17). There was significantly increased 
phosphorylation at sites p2+2a (B) in PSSM1-homozygotes compared to control horses (RR) 
(p=0.009); (mean +/- SEM, RR (n=12) RH (n=13) HH (n=3) *p<0.05). 
 
GS activity is dependent on its phosphorylation; in particular, phosphorylation of sites 3a, 3b and 
2+2a and is highly dependent on glycogen content via negative feedback [35]. Due to the 
significant increase in phosphorylation at sites 2+2a, correlation coefficients were calculated 
between site 2+2a phosphorylation and glycogen content and GS activity.  Muscle glycogen 
content was significantly, but weakly correlated with the degree of GS site 2+2a GS 
phosphorylation (R2=0.23, p=0.04); there was no significant association between phosphorylation 
at site 2+2a and GS activity (data from whole cohort; p=0.54).  
 
GLUT4, GSK3 and AMPK expression 
There was no difference in expression of GLUT4 (p=0.42), total GSK3β (p=0.49) or in the ratio of 
phosphorylated GSK3β (Ser9)  to total GSK3β (p=0.43) between different genotypes (data not 
shown). However, there was significantly higher expression of AMPKα1 protein in the PSSM1-
homozygote samples compared to WT controls (Figure 3A; p=0.04) and a trend towards elevated 
phosphorylation of AMPK (pAMPK) in PSSM1-homozygote muscle samples compared to WT and 
heterozygotes (Figure 3E), although this did not reach significance (p=0.13). There was a 
significant and strong association between AMPKα1 expression and pAMPK (Figure 3F; R2=0.66, 
p<0.0001). There was also significantly lower AMPKβ1 expression in PSSM1-homozygote 
samples compared to heterozygotes (Figure 3C; p=0.03) but not compared to WT controls.  
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Figure 3:  AMPK subunit expression and phosphorylation at Thr 172 from skeletal muscle 
extracts. There was a significant increase in AMPKα1 expression in PSSM1-homozygote 
samples (HH) compared to heterozygotes (RH) and WT controls (RR) (A; p=0.04) and a 
significant decrease in AMPKβ1 expression in the PSSM1-homozygote samples (HH) compared 
to the heterozygotes (C; p=0.03). There were no significant differences in AMPKα2 (p=0.15) or 
AMPKβ2 (p=0.28) expression between different genotypes (B and D). There was a significant 
and strong correlation between AMPKα1 and pAMPK expression (F; R2=0.66, p<0.0001). (mean 
+/- SEM, RR (n=12) RH (n=13) HH (n=3) *p<0.05). Data for A to E is normalised to the mean of 
the WT control samples. 
 
Kinetics of expressed and purified GS 
WT and mutant equine GS were expressed in insect cells and the purified enzymes were used to 
compare kinetic parameters, including dependence on G6P concentration, the Km for UDPG and 
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Vmax in the presence and absence of G6P, the Vmax/Km ratios with and without G6P, and the S0.5 
for G6P in the presence of 4.4 mM UDPG. 
 
  
Figure 4: A) Glucose-6-phosphate and B) UDPG titration (with or without 10mM G6P) 
curves for WT and R309H mutant enzyme. These curves show that the mutant enzyme has 
much higher enzyme activity at much lower concentrations of G6P and reaches its maximal 
activity at much lower G6P concentrations (A). The mutant enzyme also has a higher affinity for 
UDPG (B). (Mean +/- SEM, n=3 repeats) 
 
Table 1: Comparison of kinetics of WT and mutant (R309H) GS enzyme. Values given are 
the mean ±SEM from 3 separate experiments.  
Protein Km UDPG 
(mM) 
(-G6P) 
Km UDPG 
(mM) 
(10mM 
G6P) 
Vmax UDPG 
(mol/min.mg) 
(-G6P) 
Vmax UDPG 
(mol/min.mg) 
(10mM G6P) 
Vmax/Km 
(-G6P) 
Vmax/Km 
(10mM 
G6P) 
S0.5 G6P 
(mM) 
(4.4mM 
UDPG) 
WT GS 2.4 ±0.2 1.6 ±0.1 0.05 ±0.01 3.1 ±0.1 0.023 
±0.002 
2.0 ±0.2 3.0 ±0.4 
R309H 
GS 
0.48 ±0.01 0.18 ±0.02 0.72 ±0.06 1.9 ±0.1 1.5 ±0.3 11 ±2 0.24 ±0.03 
 
 
The G6P titration curves for the WT and the R309H mutant enzymes show that the activity of both 
enzymes increased with increasing G6P concentrations and that the mutant enzyme is nearly 
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maximally activated at G6P concentrations that barely activate the WT enzyme (Figure 4A). 
Specifically, G6P activated both the WT and mutant enzymes with an S0.5 value of around 3.0 
mM and 0.24 mM respectively (Table 1). 
 
GS activity measurements performed at varying UDPG concentrations (Figure 4B), in the 
absence and presence of maximal (10 mM) G6P, revealed that the mutant enzyme had a much 
lower Km for UDPG (0.48 and 0.18 mM, with and without G6P, respectively) than the WT enzyme 
(2.4 and 1.6 mM, with and without G6P, respectively (Table 1). The Vmax/Km ratios with and without 
G6P were also much higher for the mutant when compared to the WT GS (Table 1).   
 
Table 2: Specific activity of WT and R309H mutant GS in absence and presence of G6P 
(n=3).  
 Specific activity –G6P 
(umol/min.mg) 
Specific activity  
10mM G6P 
(umol/min.mg) 
Activity ratio 
WT GS 
0.04 
 
2.33 
 
0.02 
 
R309H GS 
0.36 
 
1.06 
 
0.34 
 
  
The R309H mutant enzyme shows an approximately 20 fold higher activity ratio than the WT 
enzyme (Table 2), due largely to the mutant enzyme’s marked activation in the absence of G6P. 
The low activity ratio seen in the WT equine GS enzyme (0.02) is similar to that detectable in 
baculovirus-generated human GS [48]. Despite both the equine WT and mutant insect-derived 
enzymes’ phosphorylation (at site 3a) (Figure 5A), the mutant equine enzyme had a high activity 
ratio, similar to that of the S7A mutant human GS, (which cannot be phosphorylated) (Figure 5B). 
Phosphatase treatment induced a marked increase in the activity ratio of both the WT equine and 
human GS enzymes from minimal baseline ratios as expected; in contrast, there was little change 
in the activity ratio of  WT equine enzyme which behaved similarly to the S7A mutant human 
enzyme (Figure 5B).  
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Figure 5: Phosphorylation (A) and Activity ratio (B) of insect derived WT and mutant 
(R309H) equine and human WT and S7A glycogen synthases. Activity ratio is minimal in both 
equine and human WT enzymes that are untreated with protein phosphatase 1 (PP1), but each 
WT enzymes’ activity ratio increased when treated with the enzyme. In contrast, the equine 
mutant enzyme has a high ratio both with and without treatment with PP1 as also seen with the 
S7A human mutant GS, despite the equine mutant enzyme’s phosphorylation. (n=3 replicates for 
each condition / enzyme; mean +/- SD). 
 
 
Glycogen synthase homology modelling   
The residues resolved in the G6P-bound crystal structure of yeast Gsy2p and the corresponding 
region of equine GS share 55% sequence overall identity (Figure 6). Conserved residues include 
the binding determinants of G6P and maltodextrin. In addition, the R309 residue and the 5 
surrounding residues of equine GS are conserved as R298 in yeast Gsy2p (Figure 6). Therefore 
Gsy2p structures with and without G6P bound, provided suitable structural templates for 
homology modelling of equine GS as a homotetramer with basal and active conformations, 
respectively (Figure 7A and B).  
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Figure 6: Sequence alignment of equine GS (Genbank accession ACB14276) and yeast 
Gsy2 (sequence in PDB ID 3NB0). Red star: R309 in equine GS and the location of the PSSM1-
associated R309H mutation. Magenta circles: predicted phosphorylation sites. Blue triangles: 
binding residues of glucose-6-phosphate. Diamonds: binding residues of maltodextrin (yellow: 
sites 1 and 2; green: sites 3 and 4).  
 
 
 22 
As a first step in understanding the structural effects of the R309H mutation, the environment 
around R309 was inspected in the WT GS models. In both basal and active GS models, R309 is 
distal from the G6P and maltodextrin binding sites (Figure  7A and B) and is therefore not 
predicted to form a direct binding contact for either substrate. Nevertheless, R309 is located on 
the C-terminal end of an α-helix that contains 4 residues (H291, Q294, H297, K301) that are G6P 
binding determinants. In addition, R309 is positioned adjacent to a pair of α-helices that use a 
coiled-coil interaction to form the major interface between subunits of the tetramer. Indeed, 
conformational transition between basal and active states involves translation and rotation around 
this central tetrameric interface [26] (Figure 7A and B).   
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Figure 7: Homology models of equine GS. (A) Basal and (B) active-state equine WT GS model 
tetramers are shown as ribbons with monomers coloured different shades of grey. Residues in 
space-fill are R309 (red), G6P-binding contacts (blue) and maltodextrin-binding contacts (yellow: 
sites 1 and 2; green: sites 3 and 4). The 309 position and local charged residues are shown as 
sticks for WT GS [(C) basal; (D) active-state] and the PSSM1-associated R309H mutant [(E) 
basal; (F) active-state]. Also shown as sticks are the corresponding residues in the crystal 
structures of yeast Gsy2p [(G) basal; (H) active-state]. Salt bridge interactions are shown as green 
dashes. 
 
 
 
R309 in the GS models and the corresponding R298 residue in the yeast Gsy2p structures have 
similar interactions (Figure 7C-H). Gsy2p R298 forms a salt bridge with the side chains of D295 
in the basal state (Figure 7G). This interaction is lost in the active state (Figure 7H) and, whereas 
R298 forms no new interactions, its former interaction partner, D295, instead forms a salt bridge 
with residue R376. R376 is located on the adjacent α-helix that forms the aforementioned coiled-
coil configuration of the enzyme subunit interface. A similar state-dependent switch in salt bridges 
is found with equine WT GS. R309 engages in a salt bridge with E306 and, as with Gsy2P, this 
interaction is lost in the active state where E306 is instead available to form a salt bridge with 
K387.   
 
The R309H mutation was introduced into GS models and the predicted outcome was the 
elimination of the salt bridge interaction with E306 in the basal-state conformation (Figure 7E). 
Release of E306 from an interaction with the 309 position may instead allow it to interact with the 
adjacent K387 even in mutant enzyme’s basal state.  
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Discussion 
The inherited skeletal muscle disorder known as PSSM1, caused by a missense mutation in the 
equine GYS1 gene [8] is histopathologically characterised by increased amylopectate and 
glycogen in skeletal muscle fibres [9, 10]. Here, we employed a multi-disciplinary approach in 
order to determine if the basis for the previously-identified, increased GS activity in PSSM1-
affected muscle [8] is associated with altered GS enzyme expression, dysregulation of GS activity, 
or a GS protein conformational change with possible constitutive activation. Our results reveal 
that the R309H mutation, responsible for this highly prevalent equine polyglucosan myopathy, 
present in over 20 breeds worldwide [12-15], is caused by constitutive activation; furthermore, we 
propose the probable mechanism, based on modelling analyses of the mutant GS structure. 
 
Similar to previous results in Quarter Horses, (a PSSM1-affected light horse breed) [49], we have 
shown that mutant draught horses with the same mutation have increased muscle glycogen 
storage despite normal GLUT4 transporter expression. Homozygous mutant muscle had 
increased GS activity compared to homozygous WT muscle, even though there was no difference 
in total GS expression between genotypes. GS in skeletal muscle from homozygous mutant 
horses had increased G6P-independent activity (%I-form), consistent with data from McCue et 
al., who detected higher GS activity, irrespective of G6P concentration, in PSSM1-affected 
Quarter Horses [8]. Despite the differences between PSSM1-homozygotes and PSSM1-
heterozygotes in terms of muscle GS activity, there was no difference between these groups in 
the glycogen content of their muscle, but the reason is unclear. As GS activity is inversely 
correlated with the extent of site 2+2a GS phosphorylation in healthy muscle [35, 38, 50], the 
higher enzyme activity in mutant horses cannot be explained by inappropriate (i.e. reduced) GS 
phosphorylation, since muscle from affected horses actually had significantly more GS 
phosphorylation at site 2+2a, (and no difference in phosphorylation at other evaluated sites) when 
compared with controls. As expected in healthy muscle [36], PSSM1-affected horses had 
increased phosphorylation at site 2+2a in the presence of elevated muscle glycogen, most likely 
reflecting a normal physiological attempt to reduce enzyme activity [35, 50-52]; indeed, the high 
GS activity in mutant horses occurs despite the phosphorylation and increased expression of 
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AMPK, the principal upstream kinase for phosphorylation at site 2. Therefore, phosphorylation of 
the mutant enzyme at site 2+2a does not correspondingly lower its activity. 
 
The increased activity detectable in PSSM1-horse muscle most likely results from a constitutive 
change in the mutant enzyme’s function, similar to that of a yeast mutant that also fails to respond 
appropriately to phosphorylation [8, 20] or to increased glycogen content [53]. In order to test this 
hypothesis, enzyme kinetic studies were performed using purified protein extracts derived from 
allele-specific GS, expressed in insect cells. These analyses revealed that the mutant enzyme 
behaves as if it is nearly fully active even in the absence of its allosteric activator, G6P as is shown 
by the significantly lower Km and increased Vmax in the absence of G6P. Further, the R309H 
enzyme had significantly lower Km for UDPG even in the absence of G6P and the Vmax/Km value 
for the mutant enzyme in the absence of G6P was increased over 60 fold, when compared to the 
WT enzyme.  In contrast, the activity ratio of the WT equine enzyme was similar to that of human 
GS purified in a similar manner [48]. Further, there was no detectable difference in the extent of 
3a phosphorylation between the WT and mutant recombinant enzymes, but despite this, the 
equine recombinant enzyme behaved similarly to that of a mutant human enzyme that cannot be 
phosphorylated, both with and without pre-treatment with protein phosphatase 1. Our data 
therefore confirm that the R309H mutation associated with PSSM1 is a true, gain of function 
mutation.  
 
The phosphorylation sites of muscle GS are located on the N- and C- termini of the enzyme [54, 
55]. We were unable to use homology modelling to investigate these sites as there are no 
corresponding regions resolved in the yeast Gsy2p structures. Nevertheless, the region around 
R309 was modelled (Figure 7) and, although not predicted to form a binding contact for G6P or 
maltodextrin (Figure 7A and B), this residue is positioned at a pivotal position near the tetrameric 
interface of the enzyme and is located on an α-helix that harbours 4 G6P binding residues. 
Therefore, a structural perturbation at the 309 position could influence the position of the 
conformational equilibrium making it easier to adopt the active conformation. Modelling indicates 
that in the enzyme’s basal state, R309 normally engages in a salt bridge with E306 whereas in 
 27 
the active state, E306 forms an alternative salt bridge with K387 (Figure 7C and D). These salt 
bridge interactions might be important for stabilising the conformation of their respective functional 
states. We therefore propose that the R309H mutation, which is predicted to eliminate the basal-
state salt bridge (Figure 7E), likely shifts the conformational equilibrium of the enzyme to the 
active state and reduces its tendency to adopt an inhibited state (Figure 7F). Interestingly, the 
residue adjacent to R309 is conserved as a glycine in both equine GS (G310) and in yeast Gsy2p 
(G299) where its mutation results in increased Gsy2p activity [20]. This glycine is located at a turn 
at the C-terminal end of the helix containing R298 (equivalent to equine R309) and G6P binding 
contacts. It is therefore positioned to function as a typical glycine-hinge residue and the reported 
mutation-associated change in enzyme activity [15], provides further evidence that structural 
deviations in this region produce constitutive activation. 
 
In summary, our work provides further evidence that the PSSM1-associated R309H GYS1 
mutation results in increased glycogen content and GS activity in skeletal muscle. We show that 
this elevated activity results in an altered sensitivity to G6P, increased affinity for UDPG and 
occurs despite hyperphosphorylation at site 2+2a and increased expression of AMPK. Further, 
for the first time, we suggest through predictive modelling a potential mechanism by which this 
occurs. Additional work is needed to explain all the phenotypic features of this equine disorder, 
including the intermittent rhabdomyolysis and gait abnormalities seen in some affected horses. 
ATP depletion is a common cause of rhabdomyolysis in humans and therefore further work 
investigating metabolic responses in affected horses might help explain some aspects of the 
clinical phenotypes in this disorder. However, our results suggest that therapeutic modification of 
AMPK activity might be ineffective in mutant animals, as increased GS phosphorylation does not 
reduce the mutant enzyme’s hyperactivity; instead, efforts aimed at direct enzyme inhibition might 
be more effective. Finally, dysregulation of GS or other related enzymes should be considered in 
humans and animals with glycogen storage diseases of unknown origin, particularly when a 
dominant mode of inheritance is identified; indeed, this common equine disease represents a 
large animal model for evaluation of treatments aimed at reducing polyglucosan formation in 
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skeletal muscle [33], a feature of a number of important, but comparatively rare, human myopathic 
disorders.  
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Supplementary data 
 
Methods 
Site directed mutagenesis and purification of hGsy1 S8,11,641,645,649,653,698A (hGsy1 
S7A): 
The human Gsy1 S7A mutant was created sequentially using the following primers in the order 
S8,11A → S8,11,641,645A → S8,11,641,645,649,653A → S8,11,641,645,649,653,698A (S7A).  
A PCR-based mutagenesis approach [56] was used to create the mutant constructs. The primers 
used in this experiment were obtained from Integrated DNA technologies. PCR amplification of 
the plasmids was performed using Pfu Ultra II fusion HS DNA polymerase obtained from Agilent 
technologies. The parental plasmid in the PCR reaction mix was digested using Dpn I (New 
England Biolabs). The Dpn I digested reaction mixture was then introduced into E. Coli DH5-α 
competent cells. The Promega WizardPlus SV mini-prep kit was used for the purification of 
plasmid from the transformed colonies. 
hGsy1 S8,11A: 
Forward primer: 5’CCGCACTTTGGCCATGTCCGCACTGCCAGGACTGG3’ 
Reverse primer: 5’CCAGTCCTGGCAGTGCGGACATGGCCAAAGTGCGG3’ 
hGsy1 S641,645A: 
Forward primer: 5’ CACGGCCAGCCGCGGTGCCACCGGCGCCCTCGCTGTC3’ 
Reverse primer: 5’ GACAGCGAGGGCGCCGGTGGCACCGCGGCTGGCCGTG3’ 
hGsy1 S649,653A: 
Forward primer: 5’ CGCCCTCGCTGGCACGACACTCCGCCCCGCACCAGAG3’ 
Reverse primer: 3’ CTCTGGTGCGGGGCGGAGTGTCGTGCCAGCGAGGGCG3’ 
hGsy1 S698A: 
Forward primer: 5’ CGCGCCGAGCGGCCTGCACCTCCTC3’ 
Reverse primer: 5’ GAGGAGGTGCAGGCCGCTCGGCGCG3’ 
The human Gsy1-S7A mutant obtained was expressed and purified as described elsewhere [48]. 
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Table S 1: Breed and signalment data for horses used in this study. Kruskal-Wallis (age) or 
chi-squared tests (sex and breed) were used with no detectable significant differences between 
groups.  
 RR (n=12) RH (n=13) HH (n=4) P value 
Age (mean+/- SD) 10 (3.3) 9.7 (3.1) 9.3 (3.4) 0.94 
Sex     
Male 6 6 2 0.98 
Female 6 7 2  
Breed     
Belgian 5 7 2 0.83 
Percheron 7 6 2  
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Figure S1: Example western blots. A) Glycogen synthase antibodies; B) upstream kinases and 
actin; C) AMPK antibodies as optimised for use in equine muscle lysates  
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